相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
C. Tanaka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants
Ophelia Q. P. Yin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
A. Davies et al.
LEUKEMIA (2009)
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Francois-Xavier Mahon et al.
CANCER RESEARCH (2008)
Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2008)
Nilotinib: A Second-Generation Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia
David L. DeRemer et al.
CLINICAL THERAPEUTICS (2008)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction
KP Yeo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
S Verstovsek et al.
CANCER (2005)
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
M Golemovic et al.
CLINICAL CANCER RESEARCH (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Interindividual and intraindividual variability of the urinary 6β-hydroxycortisol/cortisol ratio in Chinese subjects implications of its use fair evaluating CYP3A activity
OQR Yin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective
TD Bjornsson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: Correlation with alprazolam pharmacokinetics
I Gashaw et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Pharmacokinetic interactions with rifampicin - Clinical relevance
M Niemi et al.
CLINICAL PHARMACOKINETICS (2003)
Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
K Westphal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
GK Dresser et al.
CLINICAL PHARMACOKINETICS (2000)
分享论文
